AstraZeneca Commits $2 Billion to Expand Maryland Manufacturing Operations, Doubling Biologics Capacity
核心洞察
AstraZeneca announces a $2 billion investment to expand manufacturing facilities in Frederick and Gaithersburg, Maryland, supporting 2,600 jobs and nearly doubling commercial biologics (搜索) production capacity.
The expansion will enable first-time domestic production of AstraZeneca's rare disease portfolio, strengthening U.S. medicine supply chain resilience and accelerating patient access to transformative therapies.
This investment represents the fourth major U.S. manufacturing commitment in 2025, advancing AstraZeneca's historic $50 billion global investment in medicines manufacturing and R&D announced in July.
AstraZeneca announced plans to invest $2 billion to significantly expand its manufacturing footprint in Maryland, marking a major commitment to strengthen domestic pharmaceutical production capacity. The investment encompasses a substantial expansion of the company's flagship biologics (搜索) manufacturing facility in Frederick and construction of a new state-of-the-art clinical manufacturing facility in Gaithersburg, supporting 2,600 jobs across both sites.
Frederick Facility Expansion Nearly Doubles Production Capacity
The Frederick facility currently produces biologics (搜索) used across AstraZeneca's portfolio of cancer (搜索), autoimmune, respiratory and rare disease treatments. The planned expansion will nearly double commercial manufacturing capacity, enabling increased supply of existing medicines and, for the first time, production across the company's rare disease portfolio.
The Frederick expansion is expected to create 200 highly skilled jobs and 900 construction roles, with operations beginning in 2029. This marks a significant milestone as it will bring AstraZeneca's extensive rare disease portfolio onshore for the first time, according to Pascal Soriot, Chief Executive Officer of AstraZeneca.
New Gaithersburg Clinical Manufacturing Facility
In parallel, AstraZeneca will construct a new clinical manufacturing facility in Gaithersburg dedicated to the development and clinical supply of innovative molecules for clinical trials. The facility will be fully operational by 2029, creating an additional 100 jobs while retaining 400 existing roles and supporting 1,000 construction-related positions.
Both facilities will incorporate cutting-edge AI, automation and data analytics technologies while being built to the highest environmental standards, reflecting the company's commitment to advanced manufacturing practices.
Strategic Investment in U.S. Supply Chain Resilience
"Today marks a landmark moment for Maryland and American patients," said Pascal Soriot. "As the state's largest biopharmaceutical employer, we are deepening our long-standing commitment to Maryland – supporting 2,600 jobs, catalyzing economic growth and bringing our extensive rare disease portfolio onshore for the first time. This investment strengthens the resilience of the US medicines supply chain and accelerates access to transformative therapies for patients across America and around the world."
Maryland Governor Wes Moore emphasized the investment's significance for the state's biotech ecosystem: "AstraZeneca's commitment to Maryland speaks to our unique, world-class biotech ecosystem. This landmark investment affirms our reputation as a global leader in life sciences, while strengthening the U.S. medicine supply chain, accelerating the development of life-saving therapies, and creating hundreds of jobs."
Part of Historic $50 Billion Global Investment
Today's announcement represents the fourth major U.S. manufacturing investment announced by AstraZeneca in 2025, following commitments to build a new cell therapy manufacturing facility in Rockville, Maryland, a new drug substance manufacturing facility in Virginia, and expansion of the company's existing manufacturing facility in Coppell, Texas.
These investments advance AstraZeneca's historic $50 billion commitment to medicines manufacturing and R&D announced in July. The U.S. serves as AstraZeneca's largest market by sales and houses 19 R&D, manufacturing and commercial sites. The company's U.S. workforce exceeds 25,000 people and supports more than 100,000 jobs overall across the country, creating approximately $20 billion of overall value to the American economy in 2025.